Drug intelligence / Profile preview

ITI-012

Development stage: Preclinical
Lead developer: Intra-Cellular Therapies
Modality: Small Molecules
Administration: Oral

Overview

ITI-012 is a small molecule inhibitor of Casein Kinase 1 (CK1), originally developed by Intra-Cellular Therapies. CK1 is a serine/threonine kinase family implicated in various cellular processes, including circadian rhythm regulation and neuropsychiatric disorders. The ITI-012 series targets these kinases, and preclinical development focused on indications such as Alzheimer’s disease and other central nervous system disorders[7][14].

Targets

CSNK1G3 (Casein kinase 1 gamma 3)

Beyond the preview

Go deeper on ITI-012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITI-012.

Explore the full profile